Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") today announced the successful completion of Phase I with EVT 101, an NR2B subtype-specific NMDA receptor antagonist for the treatment of Alzheimer's disease and/or neuropathic pain. A total of 90 healthy, young and elderly subjects received single and multiple ascending doses of the compound. In all subjects EVT 101 was well absorbed, achieved good exposure levels, and was very well tolerated with no significant adverse events. In both the young and elderly subjects, the compound had a good pharmacokinetic profile, with an eleven hour half-life consistent with once or twice daily oral dosing.
 
The good tolerability of EVT 101 is significant given the unfavourable side-effect profile of non-selective NMDA antagonists. 
 
Contact: Anne Hennecke, Director, Investor Relations & Corporate Communications, Evotec AG, Phone: +49-40-56081-286, anne.hennecke@evotec.com